NICE Endorses Pegzilarginase for Treating Argin...

By HEOR Staff Writer

February 17, 2026

NICE Backs Pegzilarginase for Arginase Deficiency The National Institute for Health and Care Excellence (NICE) final draft guidance recommends pegzilarginase arginase deficiency trea...
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Provisional Agreement on EU Pharmaceutical Reform: Boosting Innovation and Co...
2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solut...
Repurposing Off-Patent Medicines: Insights from the EU Pilot Initiative
CTX310 Lipid Disorder: Phase 1 Trial Shows Promising LDL and Triglyceride Red...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing